CD274 and non-small cell lung carcinoma: Elevated baseline NLR (typically >3 or >5, depending on the study) has been consistently associated with worse progression-free survival (PFS) and overall survival (OS) in patients with advanced NSCLC treated with anti–PD-1 or anti–PD-L1 agents [58,59].